National Center for Advancing and Translational Sciences Genetic and Rare Diseases Information Center, a program of the National Center for Advancing and Translational Sciences

Peripheral T-cell lymphoma


Categories:
Subtypes:

FDA-Approved Treatments

The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition. Learn more orphan products.

  • Brentuximub vedotin (Brand name: Adcetris) - Manufactured by Seattle Genetics, Inc
    FDA-approved indication: November 2018, brentuximab vedotin (Adcetris) was approved for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone. In November 2016, it was approved for treatment of adult patients with primary cutaneous anaplastic large cell lymphoma. In August 2011, it was approved for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.
    National Library of Medicine Drug Information Portal
    Medline Plus Health Information
  • Belinostat (Brand name: Beleodaq) - Manufactured by Spectrum Pharmaceuticals, Inc.
    FDA-approved indication: July 2014, belinostat (Beleodaq) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma(PTCL).
    National Library of Medicine Drug Information Portal
    Medline Plus Health Information
  • Pralatrexate (Brand name: Folotyn) - Manufactured by Allos Therapeutics, Inc.
    FDA-approved indication: September 2009, pralatrexate (Folotyn) was approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    National Library of Medicine Drug Information Portal
    Medline Plus Health Information

Research helps us better understand diseases and can lead to advances in diagnosis and treatment. This section provides resources to help you learn about medical research and ways to get involved.

Clinical Research Resources

  • ClinicalTrials.gov lists trials that are related to Peripheral T-cell lymphoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

    Please note: Studies listed on the ClinicalTrials.gov website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.

Living with a genetic or rare disease can impact the daily lives of patients and families. These resources can help families navigate various aspects of living with a rare disease.

Financial Resources

  • Patient Access Network Foundation (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available. 

These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.

In-Depth Information

  • The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.

Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know.